HD-OPM Archive
Topics › Aging & longevity

Laron syndrome: lifelong low IGF1 and mTOR linked to near-absence of cancer and diabetes

Louis Nervegna · Jun 04, 2026 · ♥ 3 reactions · 0 comments · original Facebook post
Aging & longevityCancerHormones, women's & men's health
↻ This is a repost. The main version (highest ranked) is Laron syndrome, with lifelong low IGF-1 and mTOR, shows low cancer, diabetes and CVD risk · Jan 01, 2026.
AI summary & key facts

Louis reposts a rapamycin-group post explaining that Laron syndrome, which prevents the liver making IGF1, gives people low IGF1 and mTOR for life. They have almost no cancer or diabetes, reduced Alzheimer's risk and low CVD risk, which is of interest for longevity research.

(no text — see the shared post below)

Research cited

I copied this post from the rapamycin group…

If you are interested in the topics of mTOR and IGF1 and how they relate to longevity, it is worthwhile to learn something about Laron Syndrome. This rare human disease is caused by a genetic mutation that prevents the liver from making IGF1. As a result, people with Laron Syndrome naturally have low IGF1 and mTOR for their entire lives.

Cancer and diabetes are almost unheard of in people with Laron Syndrome, and they have a large reduction in risk for Alzheimer’s.

In particular, they have a low risk for developing CVD:

Paper · Nature · 2024Could a rare mutation that causes dwarfism also slow ageing?nature.com

Even though they live a relatively normal lifespan, there has never been a documented case of a person with Laron Syndrome dying of cancer (the one case mentioned in this article has been disputed). Their low IGF1 and mTOR appears to make them almost completely immune to terminal cancer.

#laronHD #igf1HD #mtorHD #cancerHD #diabetesHD #alzheimersHD #cvdHD

← newer: People with Laron syndrome (low IGF1) appear to have low carolder: Loyal raised $125M for an IGF1-lowering longevity drug for d →